# A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors

> **NCT07028281** · PHASE2 · RECRUITING · sponsor: **Suzhou Suncadia Biopharmaceuticals Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- Malignant Solid Tumors

## Interventions

- **DRUG:** SHR-4849、SHR-1316、SHR-8068、BP102、carboplatin、cisplatin

## Key facts

- **NCT ID:** NCT07028281
- **Lead sponsor:** Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-08
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07028281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07028281, "A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07028281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*